Cancer research may be facing a breakthrough.
A possible miracle drug has left doctors absolutely stunned after all patients in a trial group suffering from rectal cancer had their cancer vanish.
The group of 18 people were all given a drug named dostarlimab for six months.
Every single one of them had their tumors disappear.
Since the trial ended, the cancer has not returned for any of the patients.
Though scientists are not yet calling the drug a cure, many are saying that something of this magnitude has never occurred before.
“This is the first time this has happened in the history of cancer.” proclaimed oncologist Dr. Luis Diaz.
A trial group of people with rectal cancer just experienced something of a scientific miracle: their cancer vanished after an experimental treatment.
Patients took a drug called dostarlimab for six months which resulted in their tumors disappearing. https://t.co/LvuNvE4LnW
— NPR (@NPR) June 7, 2022
NPR has the stunning development:
A tiny group of people with rectal cancer just experienced something of a scientific miracle: their cancer simply vanished after an experimental treatment.
In a very small trial done by doctors at New York’s Memorial Sloan Kettering Cancer Center, patients took a drug called dostarlimab for six months. The trial resulted in every single one of their tumors disappearing. The trial group included just 18 people, and there’s still more to be learned about how the treatment worked. But some scientists say these kinds of results have never been seen in the history of cancer research.
All patients in this drug trial were cancer-free after 6 months. Researchers are 'excited' but cautious https://t.co/0tCK9dPMCt
— ABC News (@abcnews) June 10, 2022
An immunotherapy showed promising results in a small trial of rectal cancer patients, according to new research, but further study is needed and it is too early to call it a cure. @ErinBurnett talks to oncologist Dr. Andrea Cercek about the trial: https://t.co/0nQwlbrY65
— CNN (@CNN) June 7, 2022
"There were a lot of happy tears."
It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug.
But the results were astonishing. The cancer vanished in every single patient. https://t.co/mYnlfUkKAs
— The New York Times (@nytimes) June 5, 2022
Cancer disappears in every patient during experimental immunotherapy treatment trial https://t.co/iDUwKAbFEU
— Sky News (@SkyNews) June 8, 2022
‘Unprecedented’, ‘Remarkable’: Cancer Study Leaves Every Patient Cancer-Free https://t.co/Hj8nW0jTqQ pic.twitter.com/QWvymUhNaP
— Daily Wire (@realDailyWire) June 7, 2022
Our friends at Daily Wire have more on this remarkable study:
“I believe this is the first time this has happened in the history of cancer,” said Dr. Luis A. Diaz Jr. said, an author of the paper, The New York Times reported.
Dr. Andrea Cercek, an oncologist at Memorial Sloan Kettering Cancer Center and another author of the paper, described “a lot of happy tears” at the end of the trial.
While noting the study needs replication, Dr. Kimmie Ng, a colorectal cancer expert from the Dana-Farber Cancer Institute and an associate professor at Harvard University, called the trial results “remarkable” and “unprecedented.”
#Cancer killing medicine #dostarlimab is here pic.twitter.com/dgZUaUy6zW
— Jinil Mehta (@mehta_jinil) June 8, 2022
BREAKING REPORT: Rectal Cancer Trial Using Monoclonal Antibody Dostarlimab Finds REMISSION IN EVERY Single Patient…
— Chuck Callesto (@ChuckCallesto) June 7, 2022
https://twitter.com/GalGlassy/status/1534406688136400897?s=20&t=gzVHDWXwyfNG8EuaoEnPDA
Cancer Breakthrough? Dr Luis A. Diaz J. of Memorial Sloan Kettering Cancer Center said this was “the first time this has happened in the history of cancer”. 18 rectal cancer patients given same drug – Dostarlimab -for six months and the cancer was eliminated in every patient.
— Don Lewis (@DonLew87) June 7, 2022
Dostarlimab an immune check point inhibitor (PD1 receptor inhibitor) shows remission in 100% cases of colorectal cancer. Good news for cancer patients overall, as redirecting immune system towards cancer cells is proving to be an effective modality.
— Ranjan Kumar Patel (@docpharmaniac) June 7, 2022
Join the conversation!
Please share your thoughts about this article below. We value your opinions, and would love to see you add to the discussion!